These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2961578

  • 1. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.
    Schild HJ, Kyewski B, Von Hoegen P, Schirrmacher V.
    Eur J Immunol; 1987 Dec; 17(12):1863-6. PubMed ID: 2961578
    [Abstract] [Full Text] [Related]

  • 2. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y, Mayumi H, Eto M, Nomoto K.
    J Immunol; 1990 Mar 15; 144(6):2425-35. PubMed ID: 1968930
    [Abstract] [Full Text] [Related]

  • 3. Heterogeneity of CD4+ T cells involved in anti-allo-class I H-2 immune responses. Functional discrimination between the major proliferating cells and helper cells assisting cytotoxic T cell responses.
    Kitagawa S, Sato S, Azuma T, Shimizu J, Hamaoka T, Fujiwara H.
    J Immunol; 1991 Apr 15; 146(8):2513-21. PubMed ID: 1673140
    [Abstract] [Full Text] [Related]

  • 4. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 5. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O, Schulze-Garg C, Warnecke G, Gugel R, Löhler J, Deppert W.
    J Virol; 2001 Nov 01; 75(22):10593-602. PubMed ID: 11602701
    [Abstract] [Full Text] [Related]

  • 6. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar 01; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of L3T4-positive T lymphocytes in the generation of anti-tumor immunity in the mouse.
    Yamamoto H, Takata M, Fujimoto S.
    Jpn J Cancer Res; 1987 Feb 01; 78(2):176-84. PubMed ID: 2951356
    [Abstract] [Full Text] [Related]

  • 9. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
    Lamousé-Smith E, Clements VK, Ostrand-Rosenberg S.
    J Immunol; 1993 Dec 01; 151(11):6283-90. PubMed ID: 8245467
    [Abstract] [Full Text] [Related]

  • 10. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS, Sharrow SO, Shearer GM.
    J Immunol; 1987 Sep 15; 139(6):1840-9. PubMed ID: 2957440
    [Abstract] [Full Text] [Related]

  • 11. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A, Shiku H, Nakayama E.
    J Immunol; 1993 Jun 01; 150(11):4900-10. PubMed ID: 8496592
    [Abstract] [Full Text] [Related]

  • 12. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
    Nagarkatti M, Clary SR, Nagarkatti PS.
    J Immunol; 1990 Jun 15; 144(12):4898-905. PubMed ID: 1972170
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S.
    J Immunol; 1992 Jan 01; 148(1):285-91. PubMed ID: 1345787
    [Abstract] [Full Text] [Related]

  • 16. Sufficiency of the CD8+ T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens.
    Fan ST, Edgington TS.
    J Immunol; 1989 Dec 15; 143(12):4287-91. PubMed ID: 2531780
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD, Schreiber H, Bluestone JA.
    J Immunol; 1990 Apr 01; 144(7):2840-6. PubMed ID: 1969454
    [Abstract] [Full Text] [Related]

  • 18. Two roles for CD4 cells in the control of the generation of cytotoxic T lymphocytes.
    Cassell D, Forman J.
    J Immunol; 1991 Jan 01; 146(1):3-10. PubMed ID: 1670605
    [Abstract] [Full Text] [Related]

  • 19. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T, Shu S.
    J Immunol; 1987 Sep 15; 139(6):2103-9. PubMed ID: 2957448
    [Abstract] [Full Text] [Related]

  • 20. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H, Chang AE, Shu SY.
    Cancer Res; 1992 Mar 01; 52(5):1129-36. PubMed ID: 1531321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.